A New Brain-Sparing Anti-Obesity Drug to Avoid Adverse Cardiovascular Effects
Description
This template was adapted from the original submission. Edits were made to enhance scientific accuracy, optimal usability and/or to meet industry-leading design standards for science communication.
Anti-obesity drugs in the amphetamine (AMPH) class act on the brain to reduce appetite and increase locomotion but produce adverse cardiovascular effects. These can be circumvented by PEGylation (PEGyAMPH). PEGyAMPH does not enter the brain and protects mice against obesity, increasing lipolysis and thermogenesis, coupled to heat dissipation, becoming a novel class of exclusively peripheral anti-obesity sympathofacilitators that are devoid of any cardiovascular and brain-related side effects.
Acknowledgements
References
Mahú, I., Barateiro, A., Rial-Pensado, E., Martinéz-Sánchez, N., et al. (2020). Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects. Cell metabolism, 31(6), 1120–1135.e7. https://doi.org/10.1016/j.cmet.2020.04.013
Get started with this template for freeDon’t start from scratch.
Create professional scientific illustrations quickly and easily, even without any design expertise
- Get started with a huge library of editable icons and templates such as common biological pathways, anatomy, or genetics.
- Create figures that effectively communicate your research in half the time using our editable icons.
- Use our PDB tool to quickly generate and customize protein structures
.gif)
